Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aptinyx Inc (NQ: APTX )

2.860 USD +0.010 (+0.35%)
Official Closing Price Updated: 6:45 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aptinyx Inc

< Previous 1 2 3 Next >
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has... 
From Business Wire News Releases
Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for... 
From Business Wire News Releases
Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company... 
From Business Wire News Releases
Aptinyx to Participate in Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company... 
From Business Wire News Releases
Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company... 
From Business Wire News Releases
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a... 
From Business Wire News Releases
Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company... 
From Business Wire News Releases
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it... 
From Business Wire News Releases
Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company... 
From Business Wire News Releases
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of... 
From Business Wire News Releases
Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for... 
From Business Wire News Releases
Aptinyx to Participate in Upcoming Virtual Investor Conferences
EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,... 
From Business Wire News Releases
Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company... 
From Business Wire News Releases
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its... 
From Business Wire News Releases
Aptinyx Announces Pricing of Public Offering of Common Stock
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its... 
From Business Wire News Releases
Aptinyx Announces Proposed Public Offering of Common Stock
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to... 
From Business Wire News Releases
Thinking about buying stock in Aptinyx, Acorda Therapeutics, T-Mobile, Best Buy, or Advanced Micro Devices?
InvestorsObserver issues critical PriceWatch Alerts for APTX, ACOR, TMUS, BBY, and AMD. 
From PR Newswire
Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results... 
From Business Wire News Releases
Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has... 
From Business Wire News Releases
Aptinyx to Present at Upcoming Virtual Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company... 
From Business Wire News Releases
Aptinyx Reports Second Quarter 2020 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for... 
From Business Wire News Releases
Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company... 
From Business Wire News Releases
Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company... 
From Business Wire News Releases
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a... 
From Business Wire News Releases
Aptinyx to be Added to Russell 2000® Index
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US... 
From Business Wire News Releases
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
Data readout expected by late 2020 
From GlobeNewswire News Releases
Aptinyx to Present at Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
From GlobeNewswire News Releases
NASDAQ:APTX Shareholder Notice: Investigation over Potential Wrongdoing at Aptinyx Inc.
San Diego, CA -- (SBWIRE) -- 05/12/2020 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Aptinyx Inc. 
From SBWire - Latest Press Releases
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback